Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
RegenXBio links DMD gene therapy to improved outcomes
The updated phase 1/2 data provide evidence the pivotal gene therapy dose improves functional outcomes in older boys with the disease.
Nick Paul Taylor
Jun 5, 2025 8:52am
Keros culls phase 2 PAH program, 70 staff roles
May 29, 2025 10:10am
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
Capricor shares turn red as FDA announces deramiocel adcomm plan
May 6, 2025 8:32am
Entrada lays off 20% of staff weeks after having FDA hold lifted
Apr 30, 2025 4:38am
Wave's DMD drug remains on track in 48-week data
Mar 26, 2025 9:50am
